Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

References

• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• JerantAFJohnsonJTSheridanCDCaffreyTJEarly detection and treatment of skin cancerAm Fam Physician200062235736810929700
   PubMed Web of Science ®Google Scholar
• American Cancer Society [homepage on the Internet]Skin cancer facts Available from: http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skin-cancer-factsAccessed June 5, 2013
   Google Scholar
• ZitelliJAMohsFELarsonPSnowSMohs micrographic surgery for melanomaDermatol Clin1989748338432676291
   PubMed Web of Science ®Google Scholar
• BoyleGMTherapy for metastatic melanoma: an overview and updateExpert Rev Anticancer Ther201111572573721554048
   PubMed Web of Science ®Google Scholar
• KatipamulaRMarkovicSNEmerging therapies for melanomaExpert Rev Anticancer Ther20088455356018402522
   PubMed Web of Science ®Google Scholar
• KhanKHGoodyRBHameedHJalilACoyleVMMcAleerJJMetastatic melanoma: a regional review and future directionsTumori201298557558023235751
   PubMed Web of Science ®Google Scholar
• EigentlerTKCaroliUMRadnyPGarbeCPalliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsLancet Oncol200341274875914662431
   PubMed Web of Science ®Google Scholar
• SerroneLZeuliMSegaFMCognettiFDacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overviewJ Exp Clin Cancer Res2000191213410840932
   PubMed Web of Science ®Google Scholar
• BroseMSVolpePFeldmanMBRAF and RAS mutations in human lung cancer and melanomaCancer Res200262236997700012460918
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• FalksonCIIbrahimJKirkwoodJMCoatesASAtkinsMBBlumRHPhase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group studyJ Clin Oncol1998165174317519586887
   PubMed Web of Science ®Google Scholar
• AtkinsMBHsuJLeeSEastern Cooperative Oncology GroupPhase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200826355748575419001327
   PubMed Web of Science ®Google Scholar
• SharmaASharmaAKMadhunapantulaS VTargeting Akt3 signaling in malignant melanoma using isoselenocyanatesClin Cancer Res20091551674168519208796
   PubMed Web of Science ®Google Scholar
• BeiDMengJYouanBBEngineering nanomedicines for improved melanoma therapy: progress and promisesNanomedicine (Lond)2010591385139921128721
   PubMed Web of Science ®Google Scholar
• PachecoIBuzeaCTronVTowards new therapeutic approaches for malignant melanomaExpert Rev Mol Med201113e3322044938
   PubMed Web of Science ®Google Scholar
• TranMAWattsRJRobertsonG PUse of liposomes as drug delivery vehicles for treatment of melanomaPigment Cell Melanoma Res200922438839919493316
   PubMed Web of Science ®Google Scholar
• LangerRDrug delivery and targetingNature19983926679 SupplS5S10
   PubMed Web of Science ®Google Scholar
• DuncanRThe dawning era of polymer therapeuticsNat Rev Drug Discov20032534736012750738
   PubMed Web of Science ®Google Scholar
• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyCancer Res20137382412241723423979
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res19945449879928313389
   PubMed Web of Science ®Google Scholar
• MoghimiSMHunterACCapture of stealth nanoparticles by the body’s defencesCrit Rev Ther Drug Carrier Syst200118652755011789674
   PubMed Web of Science ®Google Scholar
• PrabhuPPatravaleVThe upcoming field of theranostic nano-medicine: an overviewJ Biomed Nanotechnol20128685988223029995
   PubMed Web of Science ®Google Scholar
• SharifSBehzadiSLaurentSForrestMLStroevePMahmoudiMToxicity of nanomaterialsChem Soc Rev20124162323234322170510
   PubMed Web of Science ®Google Scholar
• LiaoJWangCWangYLuoFQianZRecent advances in formation, properties, and applications of polymersomesCurr Pharm Des201218233432344122632981
   PubMed Web of Science ®Google Scholar
• BanghamADA correlation between surface charge and coagulant action of phospholipidsNature19611921197119813864660
   PubMed Web of Science ®Google Scholar
• OlsonFHuntCASzokaFCVailWJPapahadjopoulosDPreparation of liposomes of defined size distribution by extrusion through polycarbonate membranesBiochim Biophys Acta1979557192395096
   PubMed Web of Science ®Google Scholar
• SawantRRTorchilinV PChallenges in development of targeted liposomal therapeuticsAaps J201214230331522415612
   PubMed Web of Science ®Google Scholar
• Al-JamalWTAl-JamalKTBomansPHFrederikPMKostarelosKFunctionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancerSmall2008491406141518711753
   PubMed Web of Science ®Google Scholar
• PearsonRMSunoqrotSHsuHJBaeJ WHongSDendritic nanoparticles: the next generation of nanocarriers?Ther Deliv20123894195922946429
   PubMedGoogle Scholar
• SchilrreffPMundiña-WeilenmannCRomeroELMorillaMJSelective cytotoxicity of PAMAM G5 core – PAMAM G2.5 shell tecto-dendrimers on melanoma cellsInt J Nanomedicine201274121413322904625
   PubMed Web of Science ®Google Scholar
• RastogiRAnandSKoulVFlexible polymerosomes – an alternative vehicle for topical deliveryColloids Surf B Biointerfaces200972116116619403279
   PubMed Web of Science ®Google Scholar
• DischerBMWonYYEgeDSPolymersomes: tough vesicles made from diblock copolymersScience199928454171143114610325219
   PubMed Web of Science ®Google Scholar
• ChristianDACaiSBowenDMKimYPajerowskiJDDischerDEPolymersome carriers: from self-assembly to siRNA and protein therapeuticsEur J Pharm Biopharm200971346347418977437
   PubMed Web of Science ®Google Scholar
• PegoraroCCecchinDGraciaLSEnhanced drug delivery to melanoma cells using PMPC-PDPA polymersomesCancer Lett Epub2102013
   Web of Science ®Google Scholar
• AnilkumarPLuFCaoLFullerenes for applications in biology and medicineCurr Med Chem201118142045205921517770
   PubMed Web of Science ®Google Scholar
• ChaudhuriPSoniSSenguptaSSingle-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanomaNanotechnology201021202510219955607
   PubMed Web of Science ®Google Scholar
• YuMJambhrunkarSThornPChenJGuWYuCHyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cellsNanoscale20135117818323076766
   PubMed Web of Science ®Google Scholar
• OhJMParkDHChoiSJChoyJHLDH nanocontainers as bioreservoirs and drug delivery carriersRecent Pat Nanotechnol20126320021722747720
   PubMed Web of Science ®Google Scholar
• LiAQinLWangWThe use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune responseBiomaterials201132246947720934217
   PubMed Web of Science ®Google Scholar
• VannucciLFalvoEFornaraMSelective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticlesInt J Nanomedicine201271489150922619508
   PubMed Web of Science ®Google Scholar
• VaderPFensMHSachiniNTaxol(®)-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor(®) ELNanomedicine (Lond) Epub252013
   Web of Science ®Google Scholar
• MontanaMDucrosCVerhaeghePTermeTVanellePRathelotPAlbumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancersJ Chemother2011232596621571619
   PubMed Web of Science ®Google Scholar
• HershEMO’DaySJRibasAA phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanomaCancer2010116115516319877111
   PubMed Web of Science ®Google Scholar
• FengZZhaoGYuLGoughDHowellSBPreclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs AbraxaneCancer Chemother Pharmacol201065592393019685054
   PubMed Web of Science ®Google Scholar
• VannemanMDranoffGCombining immunotherapy and targeted therapies in cancer treatmentNat Rev Cancer201212423725122437869
   PubMed Web of Science ®Google Scholar
• ZhangXChibliHKongDNadeauJComparative cytotoxicity of gold-doxorubicin and InP-doxorubicin conjugatesNanotechnology2012232727510322710097
   PubMed Web of Science ®Google Scholar
• Lo PreteACMariaDARodriguesDGValdugaCJIbañezOCMaranhãoRCEvaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nano-emulsionJ Pharm Pharmacol200658680180816734981
   PubMed Web of Science ®Google Scholar
• NdinguriM WZheleznyakALauerJLAndersonCJFieldsGBApplication of collagen-model triple-helical peptide-amphiphiles for CD44-Targeted drug delivery systemsJ Drug Deliv2012201259260223213537
   PubMedGoogle Scholar
• KottschadeLASumanVJAmatrudaT3rdA phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1)Cancer201111781704171021472717
   PubMed Web of Science ®Google Scholar
• KottschadeLASumanVJPerezDGA randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775Cancer2013119358659222915053
   PubMed Web of Science ®Google Scholar
• OttPAChangJMaddenKOblimersen in combination with temozo-lomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trialCancer Chemother Pharmacol201371118319123064957
   PubMed Web of Science ®Google Scholar
• ChenJTargeted therapy of obesity-associated colon cancerTransl Gastrointest Cancer2012114457
   Google Scholar
• InamdarGSMadhunapantulaS VRobertsonG PTargeting the MAPK pathway in melanoma: why some approaches succeed and other failBiochemical Pharmacol2010805624637
   PubMed Web of Science ®Google Scholar
• ChenJHuangXFQiaoLKatsifisAInsulin caused drug resistance to oxaliplatin in colon cancer cell line HT29J Gastrointest Oncol20112273322811824
   PubMedGoogle Scholar
• LiYSouthTHanMChenJWangRHuangXFHigh-fat diet decreases tyrosine hydroxylase mRNA expression irrespective of obesity susceptibility in miceBrain Res2009126818118919285041
   PubMed Web of Science ®Google Scholar
• ChenJMultiple signal pathways in obesity-associated cancerObes Rev201112121063107022093240
   PubMed Web of Science ®Google Scholar
• ChenJWangMBThe roles of miRNA-143 in colon cancer and therapeutic implicationsTransl Gastrointest Cancer201212169174
   Google Scholar
• ChenJPrevention of obesity-associated colon cancer by (-)-epigallocatechin-3 gallate and curcuminTransl Gastrointest Cancer201213243249
   Google Scholar
• DhomenNDa Rocha DiasSHaywardRInducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethalityPigment Cell Melanoma Res201023111212020002887
   PubMed Web of Science ®Google Scholar
• DhomenNReis-FilhoJSda Rocha DiasSOncogenic Braf induces melanocyte senescence and melanoma in miceCancer Cell200915429430319345328
   PubMed Web of Science ®Google Scholar
• MaldonadoJLFridlyandJPatelHDeterminants of BRAF mutations in primary melanomasJ Natl Cancer Inst200395241878189014679157
   PubMed Web of Science ®Google Scholar
• CheungMSharmaAMadhunapantulaS VRobertsonG PAkt3 and mutant V600E B-Raf cooperate to promote early melanoma developmentCancer Res20086893429343918451171
   PubMed Web of Science ®Google Scholar
• ChenJMcMillanNGuWIntra-tumor injection of lentiviral-vector delivered shRNA targeting human papillomavirus E6 and E7 oncogenes reduces tumor growth in a xenograft cervical cancer model in miceJournal of Solid Tumors201224410
   Google Scholar
• MeierFBuschSLasithiotakisKCombined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatmentBr J Dermatol200715661204121317388918
   PubMed Web of Science ®Google Scholar
• BasuSHarfoucheRSoniSChimoteGMashelkarRASenguptaSNanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapyProc Natl Acad Sci U S A2009106197957796119383798
   PubMed Web of Science ®Google Scholar
• YangYLiuXZhangDChitosan/VEGF-sIRNA nanoparticle for gene silencingJ Control Release2011152Suppl 1e160e16122195822
   PubMed Web of Science ®Google Scholar
• YinDLiYLinHFunctional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivoNanotechnology2013241010510223425941
   PubMed Web of Science ®Google Scholar
• XieTXHuangFJAldapeKDActivation of stat3 in human melanoma promotes brain metastasisCancer Res20066663188319616540670
   PubMed Web of Science ®Google Scholar
• KongLYGelbardAWeiJInhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine modelClin Cancer Res20101692550256120388845
   PubMed Web of Science ®Google Scholar
• ChenYBathulaSRYangQHuangLTargeted nanoparticles deliver siRNA to melanomaJ Invest Dermatol2010130122790279820686495
   PubMed Web of Science ®Google Scholar
• TranMAGowdaRSharmaATargeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion developmentCancer Res200868187638764918794153
   PubMed Web of Science ®Google Scholar
• HockerTLSinghMKTsaoHMelanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedsideJ Invest Dermatol2008128112575259518927540
   PubMed Web of Science ®Google Scholar
• HerseyPZhangXDTreatment combinations targeting apoptosis to improve immunotherapy of melanomaCancer Immunol Immunother200958111749175919551381
   PubMed Web of Science ®Google Scholar
• ReulandSNGoldsteinNBPartykaKAABT-737 synergizes with Bortezomib to kill melanoma cellsBiol Open2012129210023213401
   PubMed Web of Science ®Google Scholar
• BenimetskayaLAyyanarKKornblumNBcl-2 protein in 518A2 melanoma cells in vivo and in vitroClin Cancer Res200612164940494816914583
   PubMed Web of Science ®Google Scholar
• BedikianAYMillwardMPehambergerHBcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupJ Clin Oncol200624294738474516966688
   PubMed Web of Science ®Google Scholar
• BeloorJChoiCSNamHYArginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNABiomaterials20123351640165022112761
   PubMed Web of Science ®Google Scholar
• PoustJCWooleryJEGreenMRManagement of toxicities associated with high-dose interleukin-2 and biochemotherapyAnticancer Drugs201324111323044722
   PubMed Web of Science ®Google Scholar
• KeilholzUEggermontAMThe role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group programCancer J Sci Am20006Suppl 1S99S10310685668
   PubMed Web of Science ®Google Scholar
• JhaGMillerJSCurtsingerJMZhangYMescherMFDudekAZRandomized Phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanomaAm J Clin Oncol Epub12132012
   Web of Science ®Google Scholar
• SchadendorfDVaubelJLivingstoneEZimmerLAdvances and perspectives in immunotherapy of melanomaAnn Oncol201223Suppl 10x104x10822987943
   PubMed Web of Science ®Google Scholar
• Mackiewicz-WysockaMZolnierekJWysockiPJNew therapeutic options in systemic treatment of advanced cutaneous melanomaExpert Opin Investig Drugs2013222181190
   PubMed Web of Science ®Google Scholar
• ZhangZTongchusakSMizukamiYInduction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen deliveryBiomaterials201132143666367821345488
   PubMed Web of Science ®Google Scholar
• PercheFBenvegnuTBerchelMEnhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNANanomedicine20117444545321220051
   PubMed Web of Science ®Google Scholar
• Ya oHNgSSHuoLFEffective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticleMol Cancer Ther20111061082109221518728
   PubMed Web of Science ®Google Scholar
• HeHGrignolVKarpaVUse of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatmentJ Control Release2011151323924521362447
   PubMed Web of Science ®Google Scholar
• SpeiserDESchwarzKBaumgaertnerPMemory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsJ Immunother201033884885820842051
   PubMed Web of Science ®Google Scholar
• StoneGWBarzeeSSnarskyVNanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanomaPLoS One2009410e733419812695
   PubMed Web of Science ®Google Scholar
• GoldingerSMDummerRBaumgaertnerPNano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patientsEur J Immunol201242113049306122806397
   PubMed Web of Science ®Google Scholar
• BaldeaIFilipAGPhotodynamic therapy in melanoma – an updateJ Physiol Pharmacol201263210911822653896
   PubMed Web of Science ®Google Scholar
• CamerinMMagaraggiaMSoncinMThe in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanomaEur J Cancer201046101910191820356732
   PubMed Web of Science ®Google Scholar
• IdrisNMGnanasammandhanMKZhangJHoPCMahendranRZhangYIn vivo photodynamic therapy using upconversion nano-particles as remote-controlled nanotransducersNat Med201218101580158522983397
   PubMed Web of Science ®Google Scholar
• SatoMYamashitaTOhkuraMN-propionyl-cysteaminylphe-nol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cellsJ Invest Dermatol200912992233224119295615
   PubMed Web of Science ®Google Scholar
• de SouzaF Fdos SantosMCdos PassosDCLimaECGuilloLACurcumin associated magnetite nanoparticles inhibit in vitro melanoma cell growthJ Nanosci Nanotechnol20111197603761022097464
   PubMed Web of Science ®Google Scholar
• ChenJRaymondKRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptorAnn Clin Microbiol Antimicrob20065316480505
   PubMedGoogle Scholar
• ChenJRaymondKNuclear receptors, bile-acid detoxification, and cholestasisLancet2006367950945445616473109
   PubMed Web of Science ®Google Scholar
• DongXMattinglyCATsengMTDoxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATPCancer Res20096993918392619383919
   PubMed Web of Science ®Google Scholar
• MengHMaiWXZhangHCodelivery of an optimal drug/ siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivoACS Nano201372994100523289892
   PubMed Web of Science ®Google Scholar
• Ahlgrimm-SiessVLaimerMArzbergerEHofmann-WellenhofRNew diagnostics for melanoma detection: from artificial intelligence to RNA microarraysFuture Oncol20128781982722830402
   PubMed Web of Science ®Google Scholar
• FerrisLKHarrisRJNew diagnostic aids for melanomaDermatol Clin201230353554522800557
   PubMed Web of Science ®Google Scholar
• CooperCSorrellJGeramiPUpdate in molecular diagnostics in melanocytic neoplasmsAdv Anat Pathol201219641041623060066
   PubMed Web of Science ®Google Scholar
• JoyceC WMurphyIGRaffertyMRyanDMcDermottE WGallagherWMTumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyondExpert Rev Proteomics20129441542322967078
   PubMed Web of Science ®Google Scholar
• MichaletXPinaudF FBentolilaLAQuantum dots for live cells, in vivo imaging, and diagnosticsScience2005307570953854415681376
   PubMed Web of Science ®Google Scholar
• KimMJLeeJYNehrbassUSongRChoiYDetection of melanoma using antibody-conjugated quantum dots in a coculture model for high-throughput screening systemAnalyst201213761440144522310726
   PubMed Web of Science ®Google Scholar
• MorosiniVBastogneTFrochotCQuantum dot-folic acid conjugates as potential photosensitizers in photodynamic therapy of cancerPhotochem Photobiol Sci201110584285121479314
   PubMed Web of Science ®Google Scholar
• ZhengHChenGDeLouiseLALouZDetection of the cancer marker CD146 expression in melanoma cells with semiconductor quantum dot labelJ Biomed Nanotechnol20106430331121323102
   PubMed Web of Science ®Google Scholar
• FecherLACummingsSDKeefeMJAlaniRMToward a molecular classification of melanomaJ Clin Oncol200725121606162017443002
   PubMed Web of Science ®Google Scholar
• OngFSDasKWangJPersonalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testingExpert Rev Mol Diagn201212659360222845480
   PubMed Web of Science ®Google Scholar
• YangHHigginsBKolinskyKAntitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancerCancer Res201272377978922180495
   PubMed Web of Science ®Google Scholar
• BollagGTsaiJZhangJVemurafenib: the first drug approved for BRAF-mutant cancerNat Rev Drug Discov2012111187388623060265
   PubMed Web of Science ®Google Scholar
• HuberFLangH PBackmannNRimoldiDGerberCHDirect detection of a BRAF mutation in total RNA from melanoma cells using cantilever arraysNat Nanotechnol20138212512923377457
   PubMed Web of Science ®Google Scholar
• BoswellCAEckPKReginoCASynthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimersMol Pharm20085452753918537262
   PubMed Web of Science ®Google Scholar
• WangLSChuangMCHoJANanotheranostics – a review of recent publicationsInt J Nanomedicine201274679469522956869
   PubMed Web of Science ®Google Scholar
• LukBTFangRHZhangLLipid- and polymer-based nanostructures for cancer theranosticsTheranostics20122121117112623382770
   PubMed Web of Science ®Google Scholar
• FraixAKandothNManetIAn engineered nanoplatform for bimodal anticancer phototherapy with dual-color fluorescence detection of sensitizersChem Commun (Camb)201349404459446123571637
   PubMed Web of Science ®Google Scholar
• MaMHaoYLiuNA novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistributionInt J Nanomedicine201273389339822848167
   PubMed Web of Science ®Google Scholar
• FonkemEUhlmannEJFloydSRMelanoma brain metastasis: overview of current management and emerging targeted therapiesExpert Rev Neurother201212101207121523082737
   PubMed Web of Science ®Google Scholar
• ScullyOJBayBHYipGYuYBreast cancer metastasisCancer Genomics Proteomics20129531132022990110
   PubMed Web of Science ®Google Scholar
• TrapéA PGonzalez-AnguloAMBreast cancer and metastasis: on the way toward individualized therapyCancer Genomics Proteomics20129529731022990109
   PubMed Web of Science ®Google Scholar
• ChenJIs Src the key to understanding metastasis and developing new treatments for colon cancer?Nat Clin Pract Gastroenterol Hepatol20085630630718477987
   PubMedGoogle Scholar
• CranmerLDTrevorKTBandlamuriSHershEMRodent models of brain metastasis in melanomaMelanoma Res200515532535616179861
   PubMed Web of Science ®Google Scholar
• KustersBde WaalRMWesselingPDifferential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanomaCancer Res200363175408541314500375
   PubMed Web of Science ®Google Scholar
• SundstrømTDaphuIWendelboIAutomated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis modelCancer Res20137382445245623423977
   PubMed Web of Science ®Google Scholar
• GottesmanMMMechanisms of cancer drug resistanceAnnu Rev Med20025361562711818492
   PubMed Web of Science ®Google Scholar
• KhdairAHandaHMaoGPanyamJNanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitroEur J Pharm Biopharm200971221422218796331
   PubMed Web of Science ®Google Scholar
• TranMASmithCDKesterMRobertsonG PCombining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor developmentClin Cancer Res200814113571358118519791
   PubMed Web of Science ®Google Scholar
• GuoPHaqueFHallahanBReifRLiHUniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnologyNucleic Acid Ther201222422624522913595
   PubMed Web of Science ®Google Scholar